JP2011246474A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011246474A5 JP2011246474A5 JP2011151443A JP2011151443A JP2011246474A5 JP 2011246474 A5 JP2011246474 A5 JP 2011246474A5 JP 2011151443 A JP2011151443 A JP 2011151443A JP 2011151443 A JP2011151443 A JP 2011151443A JP 2011246474 A5 JP2011246474 A5 JP 2011246474A5
- Authority
- JP
- Japan
- Prior art keywords
- erythropoietin
- formulation
- combination
- modified
- epo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000003951 Erythropoietin Human genes 0.000 description 27
- 108090000394 Erythropoietin Proteins 0.000 description 27
- 229940105423 erythropoietin Drugs 0.000 description 27
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 27
- 102000001554 Hemoglobins Human genes 0.000 description 21
- 108010054147 Hemoglobins Proteins 0.000 description 21
- 238000009472 formulation Methods 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- 239000002552 dosage form Substances 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 229940079593 drug Drugs 0.000 description 8
- INGWEZCOABYORO-UHFFFAOYSA-N 2-(furan-2-yl)-7-methyl-1h-1,8-naphthyridin-4-one Chemical class N=1C2=NC(C)=CC=C2C(O)=CC=1C1=CC=CO1 INGWEZCOABYORO-UHFFFAOYSA-N 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 208000015710 Iron-Deficiency Anemia Diseases 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP97110168.8 | 1997-06-21 | ||
| EP97110168A EP0885613A1 (de) | 1997-06-21 | 1997-06-21 | Verwendung von modifizierten Hämoglobinen zur Behandlung von Anämien und Kombinationspräparate umfassend Erythropoietin und modifiziertes Hämoglobin |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007113275A Division JP2007246530A (ja) | 1997-06-21 | 2007-04-23 | エリトロポエチン及び修飾ヘモグロビンを含んでいる医薬配合製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011246474A JP2011246474A (ja) | 2011-12-08 |
| JP2011246474A5 true JP2011246474A5 (enExample) | 2013-11-21 |
| JP5785008B2 JP5785008B2 (ja) | 2015-09-24 |
Family
ID=8226937
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP50365599A Withdrawn JP2002504913A (ja) | 1997-06-21 | 1998-06-03 | エリトロポエチン及び修飾ヘモグロビンを含んでいる医薬配合製剤 |
| JP2007113275A Withdrawn JP2007246530A (ja) | 1997-06-21 | 2007-04-23 | エリトロポエチン及び修飾ヘモグロビンを含んでいる医薬配合製剤 |
| JP2011151443A Expired - Lifetime JP5785008B2 (ja) | 1997-06-21 | 2011-07-08 | エリトロポエチン及び修飾ヘモグロビンを含んでいる医薬配合製剤 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP50365599A Withdrawn JP2002504913A (ja) | 1997-06-21 | 1998-06-03 | エリトロポエチン及び修飾ヘモグロビンを含んでいる医薬配合製剤 |
| JP2007113275A Withdrawn JP2007246530A (ja) | 1997-06-21 | 2007-04-23 | エリトロポエチン及び修飾ヘモグロビンを含んでいる医薬配合製剤 |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US6440932B1 (enExample) |
| EP (2) | EP0885613A1 (enExample) |
| JP (3) | JP2002504913A (enExample) |
| KR (1) | KR100519904B1 (enExample) |
| CN (1) | CN1185010C (enExample) |
| AT (1) | ATE272405T1 (enExample) |
| AU (1) | AU743475B2 (enExample) |
| BR (1) | BR9810267A (enExample) |
| CA (1) | CA2294448C (enExample) |
| DE (1) | DE59811768D1 (enExample) |
| DK (1) | DK0996462T3 (enExample) |
| ES (1) | ES2226151T3 (enExample) |
| PT (1) | PT996462E (enExample) |
| TR (1) | TR199903192T2 (enExample) |
| WO (1) | WO1998058660A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0977582B1 (de) * | 1997-03-18 | 2002-08-14 | Roche Diagnostics GmbH | Pharmazeutische kombinationspräparate enthaltend erythropoietin und eisenpräparate |
| US7345019B1 (en) * | 1999-04-13 | 2008-03-18 | The Kenneth S. Warren Institute, Inc. | Modulation of excitable tissue function by peripherally administered erythropoietin |
| ATE291436T2 (de) * | 2000-05-15 | 2005-04-15 | Hoffmann La Roche | Flüssige arzneizubereitung enthaltend ein erythropoietin derivat |
| AU3323002A (en) | 2000-12-20 | 2002-07-01 | Hoffmann La Roche | Erythropoietin conjugates |
| US20030072737A1 (en) | 2000-12-29 | 2003-04-17 | Michael Brines | Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs |
| US7767643B2 (en) | 2000-12-29 | 2010-08-03 | The Kenneth S. Warren Institute, Inc. | Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs |
| DE10215315A1 (de) * | 2002-04-05 | 2003-11-20 | Aventis Behring Gmbh Intellect | Human-Transferrin zur Behandlung der Anaemia of Chronic Disease (ACD) und des funktionellen Eisenmangels |
| US7459435B2 (en) * | 2002-08-29 | 2008-12-02 | Hoffmann-La Roche Inc. | Treatment of disturbances of iron distribution |
| US7459436B2 (en) * | 2002-11-22 | 2008-12-02 | Hoffmann-La Roche Inc. | Treatment of disturbances of iron distribution |
| WO2005032467A2 (en) | 2003-09-29 | 2005-04-14 | Warren Pharmaceuticals, Inc. | Tissue protective cytokines for the treatment and prevention of sepsis and the formation of adhesions |
| RU2273485C2 (ru) * | 2004-05-19 | 2006-04-10 | Виктор Николаевич Алейников | Железосодержащий препарат "феррал" |
| US7772182B2 (en) * | 2004-08-05 | 2010-08-10 | Alza Corporation | Stable suspension formulations of erythropoietin receptor agonists |
| EP2054074B8 (en) | 2006-08-04 | 2014-11-12 | Prolong Pharmaceuticals, LLC | Modified erythropoietin |
| AR067536A1 (es) * | 2007-07-17 | 2009-10-14 | Hoffmann La Roche | Metodo para obtener una eritropoyetina mono-pegilada en una forma sustancialmente homogenea |
| AR067537A1 (es) | 2007-07-17 | 2009-10-14 | Hoffmann La Roche | Purificacion de polipeptidos pegilados |
| WO2017091568A1 (en) | 2015-11-23 | 2017-06-01 | Bristol-Myers Squibb Company | Additive systems for use in protein pegylation |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL77081A (en) | 1984-12-04 | 1999-10-28 | Genetics Inst | Dna sequence encoding human erythropoietin process for the preparation thereof and a pharmaceutical composition of human erythropoietin |
| US4826811A (en) * | 1986-06-20 | 1989-05-02 | Northfield Laboratories, Inc. | Acellular red blood cell substitute |
| KR880012235A (ko) * | 1987-04-10 | 1988-11-26 | 벤자민 에프.람버트 | 정상 포유동물의 헤마토크릿을 증가시키는 방법 |
| JPH03112934A (ja) * | 1989-09-27 | 1991-05-14 | Mitsubishi Kasei Corp | 圧縮成型可能な粉体組成物 |
| US5631219A (en) * | 1994-03-08 | 1997-05-20 | Somatogen, Inc. | Method of stimulating hematopoiesis with hemoglobin |
| JPH09507867A (ja) * | 1994-11-17 | 1997-08-12 | バクスター、インターナショナル、インコーポレイテッド | 血液透析におけるヘモグロビン療法 |
| DE19535571A1 (de) * | 1995-09-14 | 1997-03-20 | Boehringer Mannheim Gmbh | Pharmazeutische Kombinationspräparate und deren Verwendung zur Behandlung von Hämodialysepatienten |
| WO1998008537A1 (en) | 1996-08-27 | 1998-03-05 | Hemosol Inc. | Enhanced stimulation of erythropoiesis |
-
1997
- 1997-06-21 EP EP97110168A patent/EP0885613A1/de not_active Withdrawn
-
1998
- 1998-06-03 PT PT98930785T patent/PT996462E/pt unknown
- 1998-06-03 AT AT98930785T patent/ATE272405T1/de active
- 1998-06-03 TR TR1999/03192T patent/TR199903192T2/xx unknown
- 1998-06-03 JP JP50365599A patent/JP2002504913A/ja not_active Withdrawn
- 1998-06-03 EP EP98930785A patent/EP0996462B1/de not_active Expired - Lifetime
- 1998-06-03 DK DK98930785T patent/DK0996462T3/da active
- 1998-06-03 BR BR9810267-2A patent/BR9810267A/pt not_active Application Discontinuation
- 1998-06-03 WO PCT/EP1998/003299 patent/WO1998058660A1/de not_active Ceased
- 1998-06-03 ES ES98930785T patent/ES2226151T3/es not_active Expired - Lifetime
- 1998-06-03 CA CA002294448A patent/CA2294448C/en not_active Expired - Lifetime
- 1998-06-03 AU AU81098/98A patent/AU743475B2/en not_active Expired
- 1998-06-03 US US09/446,378 patent/US6440932B1/en not_active Expired - Lifetime
- 1998-06-03 CN CNB988064324A patent/CN1185010C/zh not_active Expired - Lifetime
- 1998-06-03 KR KR10-1999-7012111A patent/KR100519904B1/ko not_active Expired - Fee Related
- 1998-06-03 DE DE59811768T patent/DE59811768D1/de not_active Expired - Lifetime
-
2002
- 2002-05-08 US US10/140,682 patent/US20020160956A1/en not_active Abandoned
-
2005
- 2005-03-28 US US11/091,876 patent/US20050197281A1/en not_active Abandoned
-
2007
- 2007-04-23 JP JP2007113275A patent/JP2007246530A/ja not_active Withdrawn
-
2011
- 2011-07-08 JP JP2011151443A patent/JP5785008B2/ja not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011246474A5 (enExample) | ||
| JP5785008B2 (ja) | エリトロポエチン及び修飾ヘモグロビンを含んでいる医薬配合製剤 | |
| Lu et al. | FDA report: Ferumoxytol for intravenous iron therapy in adult patients with chronic kidney disease | |
| JP2016514132A5 (enExample) | ||
| KR20180097596A (ko) | 메티오닌 및 아스파라긴 고갈을 이용하여 암에 대해, 인간을 포함한 포유동물을 치료하는 방법 | |
| Pandey et al. | Iron treatment strategies in dialysis-dependent CKD | |
| CN105380941A (zh) | 苯酞类化合物药物用途及其医药组合物 | |
| Singh et al. | Effect of wheat grass tablets on the frequency of blood transfusions in thalassemia major | |
| AlDallal | Voxelotor: a ray of hope for sickle disease | |
| JP2018531605A5 (enExample) | ||
| IL268930B2 (en) | Citrulline for the treatment of sickle cell crisis | |
| JP2011513496A (ja) | アポイクオリン含有組成物及びその使用方法 | |
| Gomperts et al. | Clinical Trials of Low‐Dose Carbon Monoxide | |
| US20200360428A1 (en) | Methods of Reducing Doses of Erythropoietin Stimulating Agents in Hyporesponsive Patients | |
| Kizior et al. | Saunders Nursing Drug Handbook 2026-E-Book | |
| Zahr et al. | Oral liposomal iron versus injectable iron sucrose for anemia treatment in non-dialysis chronic kidney disease patients: a non-inferiority study | |
| JPWO2020092523A5 (enExample) | ||
| RU2595840C2 (ru) | Лекарственное средство, чувствительное к комплексному соединению металл-сален, и система регуляции интракорпорального свойства для комплексного соединения металл-сален | |
| CN103768132B (zh) | 一种含注射用水溶性维生素、脂溶性维生素注射液和中/长链脂肪乳注射液的药物组合物 | |
| Basit et al. | Iron Replacement in Hemodialysis Patients–A Review | |
| CN100444836C (zh) | 含有丹参素钠的注射组合物 | |
| Sakai et al. | Intravenous infusion of Hb‐vesicles (artificial oxygen carriers) after repetitive blood exchange with a series of plasma expanders (water‐soluble biopolymers) in a rat model | |
| EP2983499B1 (en) | Food supplement compensating unfavourable vaccination effects | |
| Crarya et al. | Iron Deficiency: When and Why Oral Iron May Not Be Enough | |
| Mudge et al. | Oral iron therapies in development for iron deficiency in chronic kidney disease |